Section Arrow
Quote
INBX.NASDAQ
- Inhibrx Biosciences Inc.
Quotes are at least 15-min delayed:2025/06/02 09:24 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
13.47 
1-M High
13.875 
Volume 
-- 
Bid
13.01
Ask
14.2
Day Low
-- 
Open
-- 
1-M Low
10.84 
Market Cap 
194.99M 
Currency USD 
P/E 0.11 
%Yield -- 
10-SMA 12.97 
20-SMA 12.3 
50-SMA 12.58 
52-W High 18.95 
52-W Low 10.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
119.02/-2.14
Enterprise Value
201.44M
Balance Sheet
Book Value Per Share
6.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
200.00K
Operating Revenue Per Share
0.89
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%0PE
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%5.54PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2025/06/02 09:24 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.